Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.

Raghav K, Siena S, Takashima A, Kato T, Van den Eynde M, Pietrantonio F, Komatsu Y, Kawakami H, Peeters M, Andre T, Lonardi S, Yamaguchi K, Tie J, Castro CG, Hsu HC, Strickler JH, Kim TY, Cha Y, Barrios D, Yan Q, Kamio T, Kobayashi K, Boran A, Koga M, Allard JD, Yoshino T

Open source

DOI: 10.1016/s1470-2045(24)00380-2
Published: 2024 Sep
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-24-00380-2,
  title = {Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.},
  author = {Raghav K and Siena S and Takashima A and Kato T and Van den Eynde M and Pietrantonio F and Komatsu Y and Kawakami H and Peeters M and Andre T and Lonardi S and Yamaguchi K and Tie J and Castro CG and Hsu HC and Strickler JH and Kim TY and Cha Y and Barrios D and Yan Q and Kamio T and Kobayashi K and Boran A and Koga M and Allard JD and Yoshino T},
  year = {2024},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(24)00380-2},
  url = {https://doi.org/10.1016/s1470-2045(24)00380-2}
}

RIS

TY  - JOUR
TI  - Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.
AU  - Raghav K
AU  - Siena S
AU  - Takashima A
AU  - Kato T
AU  - Van den Eynde M
AU  - Pietrantonio F
AU  - Komatsu Y
AU  - Kawakami H
AU  - Peeters M
AU  - Andre T
AU  - Lonardi S
AU  - Yamaguchi K
AU  - Tie J
AU  - Castro CG
AU  - Hsu HC
AU  - Strickler JH
AU  - Kim TY
AU  - Cha Y
AU  - Barrios D
AU  - Yan Q
AU  - Kamio T
AU  - Kobayashi K
AU  - Boran A
AU  - Koga M
AU  - Allard JD
AU  - Yoshino T
PY  - 2024
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(24)00380-2
UR  - https://doi.org/10.1016/s1470-2045(24)00380-2
ER  -

APA

K, R., S, S., A, T., T, K., M, V. D. E., F, P., Y, K., H, K., M, P., T, A., S, L., K, Y., J, T., CG, C., HC, H., JH, S., TY, K., Y, C., D, B., Q, Y., T, K., K, K., A, B., M, K., JD, A., & T, Y. (2024). Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(24)00380-2

Source records

pubmed · retrieved 2026-09-26T18:50:33.689Z